FDAnews
www.fdanews.com/articles/70288-gog-initiates-landmark-phase-iii-trial-of-xyotax-in-ovarian-cancer

GOG Initiates Landmark Phase III Trial of Xyotax in Ovarian Cancer

March 25, 2005

The Gynecologic Oncology Group (GOG) has initiated a Phase III clinical trial examining the ability of Xyotax to maintain remission and prolong the survival of ovarian cancer patients.

The GOG will begin enrolling 1,550 patients at more than 50 main centers and 160 affiliate institutions in the U.S. and Europe over the next 18 to 24 months.

Cell Therapeutics, which is completing pivotal studies of Xyotax for the treatment of lung cancer, has been working with the GOG on developing this potentially safer, less toxic therapy in ovarian cancer. The GOG is a premier clinical trials cooperative group that has established the standards of care for the treatment of ovarian cancer in the U.S.